Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Shares of Eli Lilly (NYSE: LLY) were plunging 14.8% as of 11:14 a.m. ET on Thursday. The big drugmaker reported results for ...

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns ...

Orforglipron showed clinically meaningful results at 72 weeks, after three doses, in a pool of more than 3000 adults.

Stocks are rising on Wall Street, even as President Donald Trump’s latest tariffs kicked into effect on dozens of countries.

US stocks fell on Thursday as President Trump's sweeping tariffs hit dozens of US trade partners after his self-imposed ...

U.S. stocks are drifting lower on Thursday after U.S. President Donald Trump’s latest tariffs took effect on dozens of ...

U.S. equities were mixed in Thursday’s midday trade as investors digested the impact of President Donald Trump’s reciprocal ...

In line with the Trump administration’s goal to curb the United States’ reliance on overseas drug manufacturing, the FDA has ...